This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/528931-san-marino-sputnik-study/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Sputnik V vaccine has very low rate of severe side effects in people over 60 – San Marino study | Sputnik V vaccine has very low rate of severe side effects in people over 60 – San Marino study |
| (about 2 months later) | |
| Most people aged over 60 who have received the Russian-made Sputnik V vaccine have only experienced mild or moderate side effects, a study in San Marino has found. | Most people aged over 60 who have received the Russian-made Sputnik V vaccine have only experienced mild or moderate side effects, a study in San Marino has found. |
| A tiny independent enclave state of around 34,000, surrounded by Italian territory, San Marino began using the Russian-made vaccine in February. A study looking into adverse events following immunization (AEFIs) has appeared in the online publication EClinicalMedicine, which is run by the peer-reviewed medical journal the Lancet. | A tiny independent enclave state of around 34,000, surrounded by Italian territory, San Marino began using the Russian-made vaccine in February. A study looking into adverse events following immunization (AEFIs) has appeared in the online publication EClinicalMedicine, which is run by the peer-reviewed medical journal the Lancet. |
| A team of researchers surveyed 2,558 people aged 18 to 89 who had received at least one dose of Sputnik V, with the mean age of the recipients at 66±14 years. | A team of researchers surveyed 2,558 people aged 18 to 89 who had received at least one dose of Sputnik V, with the mean age of the recipients at 66±14 years. |
| The survey was conducted between March 4 and April 8. More than 75% of participants had at least one underlying medical condition, such as hypertension, heart problems, or obesity. | The survey was conducted between March 4 and April 8. More than 75% of participants had at least one underlying medical condition, such as hypertension, heart problems, or obesity. |
| The authors wrote that the majority of participants reported mild and moderate symptoms, with 53.3% experiencing side effects after the first dose. Overall, only 2.1% reported severe symptoms. Out of people aged 60 to 89, the reported rate of severe symptoms was even lower – 0.8%. | The authors wrote that the majority of participants reported mild and moderate symptoms, with 53.3% experiencing side effects after the first dose. Overall, only 2.1% reported severe symptoms. Out of people aged 60 to 89, the reported rate of severe symptoms was even lower – 0.8%. |
| The most frequently reported symptoms after the first dose were weakness (23.8%), headache (18.5%), joint pain (16.5%), chills (16.5%), muscle pain (16%), fever (11.9%), and malaise (11.8%). | The most frequently reported symptoms after the first dose were weakness (23.8%), headache (18.5%), joint pain (16.5%), chills (16.5%), muscle pain (16%), fever (11.9%), and malaise (11.8%). |
| Out of 1,288 people who received the second dose, 66.8% reported having felt side effects similar to those that appeared after the first dose. | Out of 1,288 people who received the second dose, 66.8% reported having felt side effects similar to those that appeared after the first dose. |
| The researchers said the results of the San Marino study confirmed the findings of Sputnik V’s phase III clinical trial, published in the Lancet in February. During the trial, the vaccine demonstrated an overall 91.6% efficacy across different age groups, and a 100% efficacy against moderate and severe cases of Covid-19. | The researchers said the results of the San Marino study confirmed the findings of Sputnik V’s phase III clinical trial, published in the Lancet in February. During the trial, the vaccine demonstrated an overall 91.6% efficacy across different age groups, and a 100% efficacy against moderate and severe cases of Covid-19. |
| San Marino passed its goal of complete immunization in over 70% of its vaccinable population in May. Since the country is not a member of the EU, it did not have to follow the European Medicines Agency, which is yet to approve the use of Sputnik V in Europe. The country also used the Pfizer vaccine in its campaign. | San Marino passed its goal of complete immunization in over 70% of its vaccinable population in May. Since the country is not a member of the EU, it did not have to follow the European Medicines Agency, which is yet to approve the use of Sputnik V in Europe. The country also used the Pfizer vaccine in its campaign. |
| The small nation was “the first country in Europe to defeat Covid and lift restrictions thanks to inclusion of Sputnik V vaccine in the national portfolio,” Kirill Dmitriev, CEO of the state-run Russian Direct Investment Fund, which funded the development of Sputnik V, said. | The small nation was “the first country in Europe to defeat Covid and lift restrictions thanks to inclusion of Sputnik V vaccine in the national portfolio,” Kirill Dmitriev, CEO of the state-run Russian Direct Investment Fund, which funded the development of Sputnik V, said. |
| “Lack of political bias in decision making helped San Marino choose the Russian vaccine, which has proven itself as one of the best in the world in terms of both safety and efficacy,” Dmitriev added. | “Lack of political bias in decision making helped San Marino choose the Russian vaccine, which has proven itself as one of the best in the world in terms of both safety and efficacy,” Dmitriev added. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |